Investor Presentaiton

10 Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 from Nimbus Therapeutics¹ • High Selectivity Allows for Greater Inhibition of TYK2 NDI-034858 is a novel, investigational, oral, allosteric inhibitor of tyrosine kinase 2 (TYK2) with high specificity for TYK2 over JAK1, JAK2, JAK3 kinases NDI-034858 Deucravacitinib TYK-2-JH2 binding KD 0.0034 nM 0.0045 nM JAK1-JH2 binding KD 5000 nM 0.49 nM Biochemical Selectivity 1.5 x 106 109 (Fold) Fold Selectivity (vs. 1.3 x 104 deucravacitinib) Source: Nimbus proprietary structure based computational modeling; side-by-side evaluation of biochemical potency of NDI-034858 and deucravacitinib (synthesized by Nimbus for nonclinical research purposes only). Potential for enhanced efficacy without introducing JAK-related toxicities Takeda • • Potential for Best-in-Class Profile Potential to demonstrate best-in-class efficacy, safety and convenience in multiple immune-mediated diseases, including psoriasis, Inflammatory Bowel Disease, psoriatic arthritis and lupus Phase 3 psoriasis study expected to start in 2023; potential for regulatory filing in FY25-27 IL-12 IL-23 IFNa/ẞ JAK2 TYK2 TYK2 JAK1 JAK2 TYK2 STAT 1-5 Source: Gangolli, et al. 2022. Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in Phase 1 studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858. 1. Transaction is expected to close before the end of FY2022, contingent on completion of review under antitrust laws

View entire presentation